NCT03005678COMPLETEDanonymous

Denosumab Versus Oral Bisphosphonate (Alendronate) for Osteoporosis in Long-term Glucocorticoid Users: an Open Randomized Controlled Trial

Sponsor

Source record

Tuen Mun Hospital

Phase

Source record

PHASE4

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Denosumab, Alendronate

Indication / condition

AI-normalized

Osteoporosis

Intervention

Source record

Denosumab, Alendronate

Related intelligence directories

Indication directory: Osteoporosis Modality directory: monoclonal antibody Target directory: Denosumab

Source & freshness

Source record

NCT ID

NCT03005678

Original source

ClinicalTrials.gov

Source last updated

Feb 12, 2020

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT03005678

Title

Denosumab Versus Oral Bisphosphonate (Alendronate) for Osteoporosis in Long-term Glucocorticoid Users: an Open Randomized Controlled Trial

Sponsor

Tuen Mun Hospital

Status

COMPLETED

Phase

PHASE4

Condition raw

Osteoporosis

Condition normalized

Osteoporosis

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

Denosumab, Alendronate

Target normalized

Denosumab, Alendronate

Interventions

Denosumab, Alendronate

Public preview

Source record

A randomized controlled trial to compare for the efficacy and tolerability of denosumab and oral alendronate in the management of glucocorticoid induced osteoporosis

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Denosumab Versus Oral Bisphosphonate (Alendronate) for Osteoporosis in Long-term Glucocorticoid Users: an Open Randomized Controlled Trial

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT03005678

Status

COMPLETED

Phase

PHASE4

Sponsor

Tuen Mun Hospital

Executive brief

Investment-Ready Snapshot

A randomized controlled trial to compare for the efficacy and tolerability of denosumab and oral alendronate in the management of glucocorticoid induced osteoporosis

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedFeb 12, 2020

Internal syncJun 11, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03005678

Indication

Osteoporosis

Modality

monoclonal antibody

Target

Denosumab, Alendronate

Intervention

Denosumab, Alendronate

Source record